Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
- Abstract
- In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.
- All Author(s)
- Seung-Hyuk Shim
; Jung-Yun Lee
; Yoo-Young Lee
; Jeong-Yeol Park
; Yong Jae Lee
; Se Ik Kim
; Gwan Hee Han
; Eun Jung Yang
; Joseph J Noh
; Ga Won Yim
; Joo-Hyuk Son
; Nam Kyeong Kim
; Tae-Hyun Kim
; Tae-Wook Kong
; Youn Jin Choi
; Angela Cho
; Hyunji Lim
; Eun Bi Jang
; Hyun Woong Cho
; Dong Hoon Suh
- Issued Date
- 2024
- Type
- Article
- Keyword
- Antibodies, Monoclonal; Gynecologic Neoplasms; Immunoconjugates; Immunotherapy; Molecular Targeted Therapy; Poly(ADP-Ribose) Polymerase Inhibitor; Survival
- Publisher
- 대한부인종양콜포스코피학회
Korean Society of Gynecologic Oncology and Colposcopy
- ISSN
- 2005-0380
; 2005-0399
- Citation Title
- Journal of gynecologic oncology
- Citation Volume
- 35
- Citation Number
- 2
- Citation Start Page
- e66
- Citation End Page
- e66
- Language(ISO)
- eng
- DOI
- 10.3802/jgo.2024.35.e66
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/3472
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.